

10/02/03


PTO/SB/08a/b (08-03)


Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449AB/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/708,635
				Filing Date	September 22, 2000
				First Named Inventor	Kendall A. Smith
				Art Unit	1648
				Examiner Name	J. Parkin
Sheet	1	of	1	Attorney Docket Number	02650/100F918-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	6,509,313 B1	01/21/03	Smith	Entire Document
	AB	4,933,433	06/12/90	Tamblyn	Entire Document
	AC	4,938,956	07/03/90	Howard	Entire Document
	AD	5,420,109	05/30/95	Suto	Entire Document
	AE	4,940,456	07/10/90	Sibalis	Entire Document
	AF	5,126,129	06/30/92	Wiltout	Entire Document


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	BA	W0 97/41831	11/13/97	Cornell Research Foundation	Entire Document	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CA	CALIGIURI, Selective Modulation of Human Natural Killer Cells In Vivo After Prolonged Infusion of Low Dose Recombinant Interleukin 2, Journal of Clinical Investigation, 1993, p. 123-132			
	CB	TEPPLER, Efficacy of Low Doses of the Polyethylene Glycol Derivative of Interleukin-2 in Modulating the Immune Response of Patients with Human Immunodeficiency Virus Type 1 Infection, Journal of Infectious Diseases, 1993; 167:291-298			
	CC	ANDERSON, Effects of Route and Formulation on Clinical Pharmacokinetics of Interleukin-2, Clinical Pharmacokinetics, 1994, 27; 1:19-31			
	CD	YAMAMOTO, Hepatic Arterial Infusion of Interleukin-2 in Advanced Hepatocellular Carcinoma, Acta Oncologica, 1993, 32; 1:43-51			
	CE	JACOBSON, Rational Interleukin 2 Therapy for HIV Positive Individuals: Daily Low Doses Enhance Immune Function Without Toxicity, Proceedings of the National Academy of Sciences of the United States of America, 1996, 93:10405-10410			
	CF	MEUER, Low Dose Interleukin-2 Induces Systemic Immune Responses Against HBsAg In Immunodeficient Non-Responders to Hepatitis B Vaccination, The Lancet, 1989, No. 8628, pp. 15-18.			
	CG	BERNSTEIN, Prolonged Administration of Low-Dose Interleukin-2 in Human Immunodeficiency Virus-Associated Malignancy Results in Selective Expansion of Innate Immune Effectors Without Significant Clinical Toxicity, Blood, 1995, 86; 9:3287-3294			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	01/24/03
--------------------	---	-----------------	----------